Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Blood (2023) 142 (Supplement 1): 7067.

https://doi.org/10.1182/blood-2023-187545

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

High Levels of Circulating Granulocytic Myeloid-Derived Suppressor Cells (G-MDSCs) Predict Failure of CD19-Targeting CAR-T Cell Therapy

Eugenio Galli, Alessandra Battaglia, Marco Fossati, Ilaria Pansini, Silvia Bellesi, Alexia Buzzonetti, Nicole Zampetti, Stefan Hohaus, Andrea Bacigalupo, Patrizia Chiusolo, Simona Sica, Andrea Fattorossi, Federica Sorà

Blood (2023) 142 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2023-186478

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

In Search of Drivers of CD34+/CD38-/CD26+ Leukemia Stem Cells Persistence in CML Patients

Paola Pacelli, Elena Bestoso, Anna Sicuranza, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Marzia Defina, Sara Fredducci, Monica Crugnola, Valentina Giai, Federica Sorà, Sara Galimberti, Donatella Raspadori, Monica Bocchia

Blood (2022) 140 (Supplement 1): 12171–12172.

https://doi.org/10.1182/blood-2022-169085

Published: 2022

Journal Articles

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

Sabrina Giammarco, Carmen Di Grazia, Anna Maria Raiola, Stefania Bregante, Riccardo Varaldo, Francesca Gualandi, Simona Sica, Patrizia Chiusolo, Federica Sora, Luca Laurenti, Elisabetta Metafuni, Andrea Bacigalupo, Emanuele Angelucci

Blood (2021) 138 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2021-147903

Published: 2021

Journal Articles

The Impact of Age in Allogeneic Stem Cell Transplantation with Thiotepa Busulfan and Fludarabine (TBF) for Myelofibrosis : A Retrospective Analysis

Federica SORA, Patrizia Chiusolo, Sabrina Giammarco, Idanna Innocenti, Francesco Autore, Elisabetta Metafuni, Eugenio Galli, maria Assunta Limongello, Luca Laurenti, Simona Sica, Andrea Bacigalupo

Blood (2021) 138 (Supplement 1): 4858.

https://doi.org/10.1182/blood-2021-145711

Published: 2021

Journal Articles

Triple Post-Transplant Cyclophosphamide (PTCY) Based Gvhd Prophylaxis for HLA Matched or HLA Haploidentical Transplants

Eugenio Galli, Elisabetta Metafuni, Sabrina Giammarco, Maria Assunta Limongiello, Idanna Innocenti, Francesco Autore, Luca Laurenti, Patrizia Chiusolo, Federica Sorà, Andrea Bacigalupo, Simona Sica

Blood (2021) 138 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2021-146581

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Cytomegalovirus and Epstein Barr Virus Reactivation after Allogeneic Stem Cell Transplantation in Pre- and Post-Letermovir Era

Elisabetta Metafuni, Sabrina Giammarco, Maria Assunta Limongiello, Filippo Frioni, Rosaria Santangelo, Federica Sora, Eugenio Galli, Idanna Innocenti, Francesco Autore, Luca Laurenti, Andrea Bacigalupo, Giuseppe Leone, Patrizia Chiusolo, Simona Sica

Blood (2021) 138 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2021-152555

Published: 2021

Journal Articles

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135972

Published: 2020

Journal Articles

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Filippo Bagnoli, MD, Vanessa Aragona, Anna Maria Barbui, MD, Stefania Bramanti, MD, Matteo Giovanni Carrabba, MD, Federica Sorà, MD, Pierluigi Zinzani, Prof, MD, Chiara Monfrini, Cristiana Carniti, Paolo Corradini

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140054

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 496.

https://doi.org/10.1182/blood-2019-127514

Published: 2019

Journal Articles

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

Patrizia Chiusolo, Andrea Bacigalupo, MD, Simona Sica, MD, Sabrina Giammarco, MD PhD, Elisabetta Metafuni, Federica Sora, MD, Luca Laurenti, MD, Francesco Autore, MD, Idanna Innocenti, MD PhD, Silvia Bellesi, Gina Zini, MD PhD, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, MD

Blood (2019) 134 (Supplement_1): 3332.

https://doi.org/10.1182/blood-2019-130849

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

Journal Articles

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Blood (2019) 134 (Supplement_1): 4153.

https://doi.org/10.1182/blood-2019-129335

Published: 2019

NARROW

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

High Levels of Circulating Granulocytic Myeloid-Derived Suppressor Cells (G-MDSCs) Predict Failure of CD19-Targeting CAR-T Cell Therapy

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

In Search of Drivers of CD34+/CD38-/CD26+ Leukemia Stem Cells Persistence in CML Patients

Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

The Impact of Age in Allogeneic Stem Cell Transplantation with Thiotepa Busulfan and Fludarabine (TBF) for Myelofibrosis : A Retrospective Analysis

Triple Post-Transplant Cyclophosphamide (PTCY) Based Gvhd Prophylaxis for HLA Matched or HLA Haploidentical Transplants

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Cytomegalovirus and Epstein Barr Virus Reactivation after Allogeneic Stem Cell Transplantation in Pre- and Post-Letermovir Era

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only